Sunday, June 26, 2022
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Pfizer and Biontech Expect to Have Omicron Variant Vaccine by March 2022

in Uncategorized
Us per capita carbon footprint looms large
Share on FacebookShare on Twitter

Pfizer and Biontech announced today that they expect to have a vaccine for the Omicron variant of Covid-19 by March 2022 if necessary to increase the level and duration of protection over it current vaccine.

The companies noted however that according to preliminary laboratory studies a third booster shot of its current vaccine neutralizes the new variant which has roiled the markets since its discovery in South Africa in November.

“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

Meanwhile early reports from South Africa suggest that the variant has had little effect on the mortality rate in Gauteng province, the epicenter of the Omicron outbreak, despite a significant rise in the number of infections. Fatalities kept trending downwards through at the beginning of December despite explosive growth of the case rate from below 5 per 100,000 in the beginning of October to above 30 per 100,000 in the December.

“A significant early finding in this analysis is the much shorter average length of stay of 2.8 days for SARS-CoV-2 positive patients admitted to the COVID wards over the last two weeks compared to an average length of stay of 8.5 days for the past 18 months,” noted the latest report from the South African Medical Research Council.

By Feike de Jong

Tags: 2022BioNTechMarchOnmicronPfizerVariant

Related Posts

Esg oversight: the corporate director’s guide
Environment

ESG Oversight: The Corporate Director’s Guide

Imf cuts global growth forecast
Uncategorized

IMF Cuts Global Growth Forecast

Healthcare technology transformation trends in the united states
Opinion

Healthcare Technology Transformation Trends in the United States

Top 100 best cities for retired singles in 2022
Uncategorized

Top 100 Best Cities for Retired Singles in 2022

Spotify lays down rules covering covid misinformation. Are they enough?
Uncategorized

Spotify lays down rules covering Covid misinformation. Are they enough?

Without cookies, online advertisers have to piece together crumbs
Uncategorized

Without Cookies, Online Advertisers Have to Piece Together Crumbs

The world’s top recipients of foreign direct investment
Uncategorized

The World’s Top Recipients of Foreign Direct Investment

Ten years to solve global crisis: pwc
Uncategorized

Ten Years to Solve Global Crisis: PwC

Saudi oil exports up in october
Uncategorized

Saudi Oil Exports up in October

Connecting as a remote ceo during covid-19: wipro’s thierry delaporte
Uncategorized

Connecting as a remote CEO during COVID-19: Wipro’s Thierry Delaporte

No Result
View All Result

Recent Posts

  • Smart Cities, Smarter Public Health
  • U.S. Consumer Sentiment Falls to Record Low
  • Hackers Steal $100 Million Worth in Latest Crypto Heist
  • Elon Musk is Worried About Tesla’s Possible Bankruptcy
  • Standing Still Is Not an Option

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    CEO Latin America | ES

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

     

    AUSTIN

    600, Congress Avenue 14th Floor
    Austin, TX.
    78701
    USA
    +1 512 649 0340

    NEW YORK

    387 Park Ave South,
    New York, NY.
    10016
    USA
    +1 212 796 64 15

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    Are you sure want to unlock this post?
    Unlock left : 0
    Are you sure want to cancel subscription?